IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) is pleased to present its quarterly report for the period ending June 30, 2025. Key highlights during and subsequent to the end of the quarter inclu ...

The Indian Air Force (IAF) is ready to bid adieu to its MiG-21 fighter jets after over 60 years of service. The Tejas Light ...

Q2 2025 Earnings Call Transcript July 22, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $2.81, expectations were $2.77. Operator: Ladies and gentlemen, thank you for standing ...

Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 HBM9378/WIN378 has the potential to be ...

AI founder Elon Musk provided an update on the company's second Memphis campus, including plans to start bringing the site ...

New York homeowners are set to receive over $2.2 billion in tax relief through the state's School Tax Relief (STAR) program, ...

Magic executive says team is willing to spend to win NBA championship, backing it up with Paolo Banchero extension and major ...

Head coach Craig Harrison says a return to the group phase is the target as The New Saints prepare to face Differdange 03 in ...

Danegaptide, a potential oral therapy for nonproliferative diabetic retinopathy, is advancing to a phase 2 trial after ...

Patients with obesity, with or without diabetes, lose up to 20% body weight and show A1c reductions with the novel agent maridebart cafraglutide, though nearly all experience GI side effects.

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, prevalent gastrointestinal side effects are leading the company to use a ...